Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio (Nasdaq: ACET) announced an inducement grant awarded on December 31, 2024. The company granted one new employee non-qualified stock options to purchase 9,000 shares of common stock at an exercise price of $0.96 per share. The vesting schedule includes 25% after one year, with the remaining 75% vesting monthly over three years, completing full vesting on the fourth anniversary. The grant was made under Adicet's 2022 Inducement Plan, approved outside the stockholder-approved equity incentive plans, and authorized by the compensation committee as a material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET) ha annunciato un'assegnazione di incentivo avvenuta il 31 dicembre 2024. L'azienda ha concesso a un nuovo dipendente opzioni su azioni non qualificate per acquistare 9.000 azioni ordinarie a un prezzo di esercizio di 0,96 $ per azione. Il piano di maturazione prevede il 25% dopo un anno, con il restante 75% che matura mensilmente per tre anni, completando la maturazione totale al quarto anniversario. L'assegnazione è stata effettuata nell'ambito del Piano di Incentivazione 2022 di Adicet, approvato al di fuori dei piani di incentivazione azionaria approvati dagli azionisti, ed è stata autorizzata dal comitato per la compensazione come incentivo sostanziale per l'assunzione in conformità con la Regola 5635(c)(4) di Nasdaq.
Adicet Bio (Nasdaq: ACET) anunció una concesión de incentivo realizada el 31 de diciembre de 2024. La compañía otorgó a un nuevo empleado opciones sobre acciones no calificadas para comprar 9,000 acciones ordinarias a un precio de ejercicio de $0.96 por acción. El calendario de adquisición incluye un 25% después de un año, con el 75% restante adquiriéndose mensualmente durante tres años, completando la adquisición total en el cuarto aniversario. La concesión se realizó bajo el Plan de Incentivo 2022 de Adicet, aprobado fuera de los planes de incentivo de capital aprobados por los accionistas, y autorizado por el comité de compensación como un incentivo material para el empleo de acuerdo con la Regla de Listado 5635(c)(4) de Nasdaq.
Adicet Bio (Nasdaq: ACET)는 2024년 12월 31일에 인센티브 보상을 발표했습니다. 이 회사는 한 신규 직원에게 9,000주의 보통주를 주당 $0.96의 행사 가격으로 매수할 수 있는 비정규 주식 옵션을 부여했습니다. 베스팅 일정은 1년 후에 25%, 나머지 75%는 3년 동안 매월 베스팅되며, 네 번째 기념일에 전체 베스팅이 완료됩니다. 이번 부여는 Adicet의 2022 인센티브 계획에 따라 이루어졌으며, 주주 승인 주식 인센티브 계획 외부에서 승인되었고, Nasdaq 상장 규칙 5635(c)(4)에 따라 고용을 위한 실질적인 인센티브로 보상 위원회에 의해 승인되었습니다.
Adicet Bio (Nasdaq: ACET) a annoncé une attribution d'incitation le 31 décembre 2024. L'entreprise a accordé à un nouvel employé des options d'achat d'actions non qualifiées pour acquérir 9 000 actions ordinaires à un prix d'exercice de 0,96 $ par action. Le calendrier d'acquisition comprend 25 % après un an, le reste de 75 % étant acquis mensuellement sur trois ans, ce qui complète l'acquisition totale au quatrième anniversaire. L'attribution a été effectuée dans le cadre du Plan d'Incitation 2022 d'Adicet, approuvé en dehors des plans d'incitation en actions approuvés par les actionnaires, et autorisé par le comité de rémunération en tant qu'incitation matérielle à l'emploi conformément à la règle de cotation 5635(c)(4) de Nasdaq.
Adicet Bio (Nasdaq: ACET) gab am 31. Dezember 2024 eine Anreizvergabe bekannt. Das Unternehmen gewährt einem neuen Mitarbeiter nicht qualifizierte Aktienoptionen zum Kauf von 9.000 Aktien zum Ausübungspreis von 0,96 $ pro Aktie. Der Vesting-Zeitplan umfasst 25 % nach einem Jahr, während die verbleibenden 75 % monatlich über drei Jahre erwerben werden, was zur Vollverzinsung am vierten Jahrestag führt. Die Vergabe erfolgte im Rahmen des Anreizplans 2022 von Adicet, der außerhalb der von den Aktionären genehmigten Eigenkapitalanreizpläne genehmigt wurde und vom Vergütungsausschuss als materieller Anreiz für die Beschäftigung gemäß Nasdaq-Listing-Regel 5635(c)(4) genehmigt wurde.
- None.
- None.
One individual was hired by Adicet in December 2024 and granted new hire non-qualified stock options to purchase 9,000 shares of Adicet’s common stock with an exercise price of
The above-described award was granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to Adicet’s 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The award was authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employee entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241231271669/en/
Adicet Bio, Inc.
Investor and Media Contacts
Investors:
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com
Media:
Kerry Beth Daly
kbdaly@adicetbio.com
Source: Adicet Bio, Inc.
FAQ
What is the exercise price of ACET's December 2024 inducement grant?
How many shares were included in ACET's December 2024 inducement grant?
What is the vesting schedule for ACET's December 2024 inducement grant?
Under which plan was ACET's December 2024 inducement grant issued?
